Brivanib
Brivanib (BMS-540215) is a potent, ATP-competitive VEGFR2 inhibitor (IC50=25 nM) with additional activity against VEGFR-1 and FGFR-1, but significantly less potency against PDGFR-β. This investigational compound has been evaluated in Phase 3 clinical trials for oncology research, supporting its use in both in vitro and in vivo studies of angiogenesis and tumor growth.
Product Specifications
CAS Number
649735-46-6
Product Name Alternative
Autophagy, BMS 540215, BMS540215, BMS-540215, Brivanib, Inhibitor, EGFR, FGFR1, Flk1, inhibit, VEGFR2, VEGFR, VEGFR1, Vascular endothelial growth factor receptor
Field of Research
Cardiovascular Research, Cell Biology, Signal Transduction
Purity
98.87% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.4 mM) ; H2O:<1 mg/mL; Ethanol:3 mg/mL (8.1 mM) ; DMSO:69 mg/mL (186.3 mM)
Smiles
C[C@@H] (O) COc1cn2ncnc (Oc3ccc4[nH]c (C) cc4c3F) c2c1C
Molecular Formula
C19H19FN4O3
Molecular Weight
370.38
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
